Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06712836 · ClinicalTrials.gov registry record · Phase 2
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
A Phase 2 study of Obesity and Overweight or Obesity, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- Active
- Registry status
- Phase 2
- Development phase
- 225
- Enrollment target
- 2
- Study locations
NCT06712836 is a Phase 2 study of Obesity and Overweight or Obesity that is active but no longer recruiting, run by Metsera, a wholly owned subsidiary of Pfizer. The registered enrollment target is 225 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (73% lower). The trial reports 2 study locations across 2 states.
The verdict
NCT06712836, a Phase 2 study of Obesity and Overweight or Obesity, is active but no longer recruiting, sponsored by Metsera, a wholly owned subsidiary of Pfizer.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 225 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose levels. Participants who have completed the first 28 weeks may participate in an exploratory extension study.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG MET097
Study Locations (2)
California
- Research Site MET097 24-201-001 - Anaheim
Florida
- Research Site MET097 24-201-002 - Hollywood
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 225 participants |
| Start Date | 2024-10-24 |
| Est. Completion | 2026-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06712836
The ClinicalTrials.gov registry entry for NCT06712836 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 225 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (73% lower). The listed sponsor is Metsera, a wholly owned subsidiary of Pfizer, which has 7 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06712836 reports 2 study locations spanning 2 distinct geographic areas - top geographies include California, Florida.
Frequently Asked Questions
What is clinical trial NCT06712836 about?
NCT06712836 is a clinical study titled "A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight". This study is designed to test how well MET097, an active drug, works to treat individuals with obesity or overweight when compared to placebo. MET097 or placebo will be given to individuals weekly for 28 weeks. If an individual is assigned to MET097 they will receive one of four different dose leve...
What is the current status of trial NCT06712836?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 225 participants. The study started on 2024-10-24. Estimated completion is 2026-05.
What conditions does trial NCT06712836 study?
This clinical trial studies the following conditions: Obesity, Overweight or Obesity.
What interventions are being tested in trial NCT06712836?
The interventions under investigation include: Placebo (DRUG), MET097 (DRUG).
Who is sponsoring clinical trial NCT06712836?
This trial is sponsored by Metsera, a wholly owned subsidiary of Pfizer, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06712836 being conducted?
This trial has 2 study locations across California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
TIRzepatide for the Treatment of Obesity in Patients With Atrial Fibrillation
RECRUITING · Phase 2
-
Tirzepatide: Reversal of Lipotoxicity and Adipose Tissue Dysfunction in Humans With Overweight/Obesity
RECRUITING · Phase 2
-
Convergent Mechanisms Underlying Reprometabolic Syndrome in Women
RECRUITING · Phase 2
-
Arterial Destiffening Effects of SGLT2 Inhibition in Veterans With Obesity
RECRUITING · Phase 2
-
A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight
RECRUITING · Phase 2
-
Pharmacological and Behavioral Treatment After Bariatric Surgery
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.